A Novel Treatment Option for Distributive Shock (Non-CE Presentation)

PRESENTED BY:
John Devin, Pharm.D., FCCM, FCCP, BCCP

Critical Care Pharmacist and Clinical Scientist

Tufts Medical Center

Boston, MA

WHEN:
Tuesday, July 31, 2018 

LOCATION:
Just Restaurant

2280 U.S. Hwy 9 South

Old Bridge, NJ 08857

(732) 707-4800

TIME:
6:30 PM sign in (must pre-register)

OBJECTIVES:

1. Describe the importance of maintaining a MAP > 65 mmHg in patients with distributive shock
2. Distinguish the pharmacology and pharmacokinetics of angiotensin II with norepinephrine and vasopressin
3. Describe the primary and secondary efficacy and safety results of the ATHOS-3 trial
4. Develop a plan for the appropriate initiation and monitoring of angiotensin II in a patient with distributive/septic shock

REGISTRATION CLOSED.

This program is sponsored by: La Jolla Pharmaceuticals.

This is not an independent educational program, and no CME credits will be provided.